ABSTRACT
Traumatic brain injury (TBI)-related hypopituitarism has been recognized as a clinical entity for more than a century, with the first case being reported in 1918. However, during the 20th century hypopituitarism was considered only a rare sequela of TBI. Since 2000 several studies strongly suggest that TBI-mediated pituitary hormones deficiency may be more frequent than previously thought. Growth hormone deficiency (GHD) is the most common abnormality, followed by hypogonadism, hypothyroidism, hypocortisolism, and diabetes insipidus. The pathophysiological mechanisms underlying pituitary damage in TBI patients include a primary injury that may lead to the direct trauma of the hypothalamus or pituitary gland; on the other hand, secondary injuries are mainly related to an interplay of a complex and ongoing cascade of specific molecular/biochemical events. The available data describe the importance of GHD after TBI and its influence in promoting neurocognitive and behavioral deficits. The poor outcomes that are seen with long standing GHD in post TBI patients could be improved by GH treatment, but to date literature data on the possible beneficial effects of GH replacement therapy in post-TBI GHD patients are currently scarce and fragmented. More studies are needed to further characterize this clinical syndrome with the purpose of establishing appropriate standards of care. The purpose of this review is to summarize the current state of knowledge about post-traumatic GH deficiency.
Subject(s)
Brain Injuries, Traumatic/diagnosis , Brain Injuries, Traumatic/epidemiology , Brain Injuries, Traumatic/therapy , Growth Hormone/deficiency , Human Growth Hormone/deficiency , Hypopituitarism/complications , Pituitary Gland/metabolism , Animals , Body Composition , Bone Density , Brain Injuries/complications , Brain Injuries/drug therapy , Cardiovascular Diseases/complications , Hormone Replacement Therapy/adverse effects , Humans , Hypothalamus/metabolism , Hypothyroidism/complications , Insulin-Like Growth Factor I/metabolism , Quality of Life , Risk FactorsABSTRACT
The diagnosis of short stature (SS) is of widespread importance for later treatment. In the present paper, a metabolomic method was used to analyze the metabolic characteristics of SS children caused by endocrine metabolic diseases in order to understand the underlying biochemical mechanism and provide a potential intervention strategy for SS. According to the clinical diagnosis and family investigation, all patients with SS were confirmed to be due to the endocrine disorders, especially GH deficiency (GHD). A nuclear magnetic resonance (NMR)-based metabolomic analysis of serum was used to identify the metabolic changes in 45 SS children from the 35 healthy controls (HCs). The disturbed metabolic network related to SS was correspondingly derived from the differential metabolites. The SS children demonstrated higher serum levels of citrate, phenylalanine, creatinine, and tyrosine and lower serum levels of glucose, serine, betaine, inositol, lysine, glycerol, and glutamine compared with the HCs. The results demonstrated that the disturbed glucose metabolism and metabolism and biosynthesis of amino acids are typical metabolic features of SS, and the lower levels of lysine and glutamine are the metabolic characterization of the affected growth axes and stress state of SS, respectively. The significant changes of those serum metabolites are able to be regarded as potential biomarkers for the diagnosis of SS. Accordingly, supplemental betaine in dietary pattern, the improvement of glycometabolism, and endogenous replenishment of lysine and glutamine allow the possible treatment strategy for SS.
Subject(s)
Growth Disorders/blood , Human Growth Hormone/deficiency , Metabolomics/methods , Adolescent , Biomarkers/blood , Blood Glucose/metabolism , Case-Control Studies , Child , Child, Preschool , Female , Humans , Lipids/blood , Male , Metabolic Networks and Pathways/physiology , Metabolome/physiologyABSTRACT
OPINION STATEMENT: Survival rates of childhood cancer have improved markedly, and today more than 80 % of those diagnosed with a pediatric malignancy will become 5-year survivors. Nevertheless, survivors exposed to cranial radiotherapy (CRT) are at particularly high risk for long-term morbidity, such as endocrine insufficiencies, metabolic complications, and cardiovascular morbidity. Deficiencies of one or more anterior pituitary hormones have been described following therapeutic CRT for primary brain tumors, nasopharyngeal tumors, and following prophylactic CRT for childhood acute lymphoblastic leukemia (ALL). Studies have consistently shown a strong correlation between the total radiation dose and the development of pituitary deficits. Further, age at treatment and also time since treatment has strong implications on pituitary hormone deficiencies. There is evidence that the hypothalamus is more radiosensitive than the pituitary and is damaged by lower doses of CRT. With doses of CRT <50 Gy, the primary site of radiation damage is the hypothalamus and this usually causes isolated GH deficiency (GHD). Higher doses (>50 Gy) may produce direct anterior pituitary damage, which contributes to multiple pituitary deficiencies. The large group of ALL survivors treated with CRT in the 70-80-ties has now reached adulthood, and these survivors were treated mainly with 24 Gy, and the vast majority of these patients suffer from GHD. Further, after long-term follow-up, insufficiencies in prolactin (PRL) and thyroid stimulating hormone (TSH) have also been reported and a proportion of these patients were also adrenocoticotrophic hormone (ACTH) deficient. CRT to the hypothalamus causes neuroendocrine dysfunction, which means that the choice of GH test is crucial for the diagnosis of GHD.
Subject(s)
Brain Neoplasms/secondary , Cranial Irradiation/adverse effects , Hypothalamus/radiation effects , Pituitary Gland/radiation effects , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/deficiency , Brain Neoplasms/complications , Brain Neoplasms/radiotherapy , Child , Child, Preschool , Gonadotropins/blood , Gonadotropins/deficiency , Human Growth Hormone/blood , Human Growth Hormone/deficiency , Humans , Hypothalamus/metabolism , Pituitary Gland/metabolism , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Prolactin/blood , Prolactin/deficiency , ROC Curve , Thyrotropin/blood , Thyrotropin/deficiency , Time Factors , Treatment OutcomeABSTRACT
Growth hormone deficiency affects roughly between one in 3000 and one in 4000 children with most instances of growth hormone deficiency being idiopathic. Growth hormone deficiency can also be associated with genetic diseases or chromosome abnormalities. Association of growth hormone deficiency together with hypothalamic-pituitary axis malformation and Cat-Eye syndrome is a very rare condition. We report a family with two brothers presenting with growth delay due to a growth hormone deficiency associated with a polymalformation syndrome. They both displayed pre-auricular pits and tags, imperforate anus and Duane retraction syndrome. Both parents and a third unaffected son displayed normal growth pattern. Cerebral MRI showed a hypothalamic-pituitary axis malformation in the two affected brothers. Cytogenetic studies revealed a type I small supernumerary marker chromosome derived from chromosome 22 resulting in a tetrasomy 22pter-22q11.21 characteristic of the Cat-Eye syndrome. The small supernumerary marker chromosome was present in the two affected sons and the mother in a mosaic state. Patients with short stature due to growth hormone deficiency should be evaluated for chromosomal abnormality. Family study should not be underestimated.
Subject(s)
Chromosome Disorders/diagnosis , Eye Abnormalities/diagnosis , Human Growth Hormone/deficiency , Pituitary Gland/abnormalities , Abnormalities, Multiple/genetics , Aneuploidy , Chromosome Aberrations , Chromosome Disorders/drug therapy , Chromosome Disorders/genetics , Chromosomes, Human, Pair 22/genetics , Eye Abnormalities/drug therapy , Eye Abnormalities/genetics , Hormone Replacement Therapy , Human Growth Hormone/therapeutic use , Humans , Hypothalamus/abnormalities , In Situ Hybridization, Fluorescence , Infant, Newborn , Karyotyping , MaleSubject(s)
Bone Density Conservation Agents/pharmacology , Bone Density/drug effects , Calcium/pharmacology , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Vitamin D/pharmacology , Zinc/pharmacology , Adolescent , Bone Density Conservation Agents/administration & dosage , Calcium/administration & dosage , Child , Dietary Supplements , Human Growth Hormone/administration & dosage , Humans , India , Pilot Projects , Treatment Outcome , Vitamin D/administration & dosage , Zinc/administration & dosageABSTRACT
CONTEXT: Endocrine problems are common in patients with Fanconi anemia (FA). About 80% of children and adults with FA have at least one endocrine abnormality, including short stature, GH deficiency, abnormal glucose or insulin metabolism, dyslipidemia, hypothyroidism, pubertal delay, hypogonadism, or impaired fertility. The goal of this report is to provide an overview of endocrine abnormalities and guidelines for routine screening and treatment to allow early diagnosis and timely intervention. EVIDENCE ACQUISITION: This work is based on a comprehensive literature review, including relevant articles published between 1971 and 2014, and proceedings of a Consensus Conference held by the Fanconi Anemia Research Fund in 2013. EVIDENCE SYNTHESIS: The panel of experts collected published evidence and discussed its relevance to reflect current information about the endocrine care of children and adults with FA before the Consensus Conference and through subsequent deliberations that led to the consensus. CONCLUSIONS: Individuals with FA should be routinely screened for endocrine abnormalities, including evaluation of growth; glucose, insulin, and lipid metabolism; thyroid function; puberty; gonadal function; and bone mineral metabolism. Inclusion of an endocrinologist as part of the multidisciplinary patient care team is key to providing comprehensive care for patients with FA.
Subject(s)
Endocrine System Diseases/diagnosis , Endocrine System Diseases/therapy , Fanconi Anemia/diagnosis , Fanconi Anemia/therapy , Mass Screening/standards , Practice Guidelines as Topic , Adult , Child , Endocrine System Diseases/etiology , Fanconi Anemia/complications , Glucose Metabolism Disorders/diagnosis , Glucose Metabolism Disorders/etiology , Glucose Metabolism Disorders/therapy , Growth Disorders/diagnosis , Growth Disorders/etiology , Growth Disorders/therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Humans , Malnutrition/diagnosis , Malnutrition/etiology , Malnutrition/therapy , Mass Screening/methods , Thinness/diagnosis , Thinness/etiology , Thinness/therapyABSTRACT
BACKGROUND: Children initially diagnosed with isolated GH deficiency (IGHD) have a variable rate to progress to combined pituitary hormone deficiency (CPHD) during follow-up. OBJECTIVE: To evaluate the development of CPHD in a group of childhood-onset IGHD followed at a single tertiary center over a long period of time. PATIENTS AND METHODS: We retrospectively analyzed data from 83 patients initially diagnosed as IGHD with a mean follow-up of 15.2 years. The Kaplan-Meier method and Cox regression analysis was used to estimate the temporal progression and to identify risk factors to development of CPHD over time. RESULTS: From 83 patients initially with IGHD, 37 (45%) developed CPHD after a median time of follow up of 5.4 years (range from 1.2 to 21 years). LH and FSH deficiencies were the most common pituitary hormone (38%) deficiencies developed followed by TSH (31%), ACTH (12%) and ADH deficiency (5%). ADH deficiency (3.1 ± 1 years from GHD diagnosis) presented earlier and ACTH deficiency (9.3 ± 3.5 years) presented later during follow up compared to LH/FSH (8.3 ± 4 years) and TSH (7.5 ± 5.6 years) deficiencies. In a Cox regression model, pituitary stalk abnormalities was the strongest risk factor for the development of CPHD (hazard ratio of 3.28; p = 0.002). CONCLUSION: Our study indicated a high frequency of development of CPHD in patients initially diagnosed as IGHD at childhood. Half of our patients with IGHD developed the second hormone deficiency after 5 years of diagnosis, reinforcing the need for lifelong monitoring of pituitary function in these patients.
Subject(s)
Adrenocorticotropic Hormone/deficiency , Dwarfism, Pituitary/epidemiology , Follicle Stimulating Hormone/deficiency , Human Growth Hormone/deficiency , Hypopituitarism/epidemiology , Luteinizing Hormone/deficiency , Thyrotropin/deficiency , Vasopressins/deficiency , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Disease Progression , Female , Follow-Up Studies , Humans , Hypopituitarism/pathology , Hypothalamus/pathology , Kaplan-Meier Estimate , Longitudinal Studies , Magnetic Resonance Imaging , Male , Pituitary Gland/pathology , Proportional Hazards Models , Retrospective Studies , Time Factors , Young AdultABSTRACT
OBJECTIVE: Hypertrophic obesity is associated with impaired insulin sensitivity and lipid-mobilizing activity of zinc-α2-glycoprotein. Adipose tissue (AT) of growth hormone (GH) -deficient patients is characterized by extreme adipocyte hypertrophy due to defects in AT lipid metabolism. It was hypothesized that zinc-α2-glycoprotein is regulated by GH and mediates some of its beneficial effects in AT. METHODS: AT from patients with GH deficiency and individuals with obesity-related GH deficit was obtained before and after 5-year and 24-month GH supplementation therapy. GH action was tested in primary human adipocytes. Relationships of GH and zinc-α2-glycoprotein with adipocyte size and insulin sensitivity were evaluated in nondiabetic patients with noncancerous cachexia and hypertrophic obesity. RESULTS: AT in GH-deficient adults displayed a substantial reduction of zinc-α2-glycoprotein. GH therapy normalized AT zinc-α2-glycoprotein. Obesity-related relative GH deficit was associated with almost 80% reduction of zinc-α2-glycoprotein mRNA in AT. GH increased zinc-α2-glycoprotein mRNA in both AT of obese men and primary human adipocytes. Interdependence of GH and zinc-α2-glycoprotein in regulating AT morphology and metabolic phenotype was evident from their relationship with adipocyte size and AT-specific and whole-body insulin sensitivity. CONCLUSIONS: The results demonstrate that GH is involved in regulation of AT zinc-α2-glycoprotein; however, the molecular mechanism linking GH and zinc-α2-glycoprotein in AT is yet unknown.
Subject(s)
Adipose Tissue/drug effects , Human Growth Hormone/administration & dosage , Obesity/metabolism , Seminal Plasma Proteins/metabolism , Adipocytes/drug effects , Adipocytes/metabolism , Adipose Tissue/metabolism , Administration, Oral , Adult , Aged , Case-Control Studies , Cohort Studies , Dietary Supplements , Female , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Humans , Lipid Metabolism , Male , Middle Aged , Zn-Alpha-2-GlycoproteinABSTRACT
The growth hormone deficiency (GHD) syndrome is associated with several metabolic abnormalities and it has been postulated that the increased cardiovascular disease (CVD) morbidity and mortality in GHD patients may be related to the missing metabolic effects of GH. Many CVD risk factors show improvements after GH therapy. Reduced bone mineral density (BMD) has been recorded both in patients with isolated GHD and in those with multiple pituitary deficiencies, indicating that GHD per se is responsible for the low BMD in both types of patients. These matters are, however, more complicated, as hypopituitary patients with GHD may have different phenotypes due to differences in underlying diagnoses. These phenotypes may not be clear-cut in individual patients. Moreover, patients may transit between different phenotypes over time due to extension of the pathology in the pituitary and/or the consequences of the treatment (surgery and/or radiotherapy). Three different phenotypes of hypopituitary patients will be discussed, with a focus on CVD risk and bone health: (1) patients with isolated GHD, e.g. due to prophylactic cranial radiotherapy for lymphoblastic leukaemia in childhood; (2) patients with GHD and multiple hormone deficiencies due to pituitary macroadenomas treated by surgery; (3) patients with GHD caused by craniopharyngiomas with multiple hormone deficiencies and hypothalamic involvement, where hypothalamic damage frequently dominates the positive metabolic effects of GH therapy. These phenotypes illustrate the differential impact of various pituitary pathologies on the phenotype of patients with GHD.
Subject(s)
Endocrine System Diseases/drug therapy , Hormone Replacement Therapy/methods , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Animals , Bone Density/drug effects , Bone Density/physiology , Cardiovascular Diseases/chemically induced , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/metabolism , Endocrine System Diseases/blood , Endocrine System Diseases/diagnosis , Hormone Replacement Therapy/adverse effects , Humans , Hypothalamus/drug effects , Hypothalamus/metabolismSubject(s)
Growth Disorders/drug therapy , Growth Disorders/nursing , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Play Therapy , Stress, Psychological/prevention & control , Child, Preschool , Growth Disorders/complications , Humans , Male , Nurse-Patient Relations , Stress, Psychological/complicationsABSTRACT
BACKGROUND: Growth hormone deficiency (GHD) in adulthood may be associated with a decreased bone mineral density (BMD), a decreased bone mineral content (BMC) and an increased fracture risk. Recombinant human GH (rhGH) replacement induces a progressive increase in BMD for up to 5-7 years of treatment. Data on longer follow-up are, however, scarce. METHODS: Two hundred and thirty-adult GHD patients (mean age 47·1 years, 52·6% female), of whom 88% patients had adult-onset (AO) GHD, receiving rhGH replacement for ≥5 years were included in the study. Most patients had multiple pituitary hormone deficiencies. Bone turnover markers, BMC and BMD and T-scores at the lumbar spine and femoral neck were evaluated at baseline, and after 5, 10 and 15 years of rhGH replacement. In addition, clinical fracture incidence was assessed. RESULTS: Mean lumbar spine BMD, lumbar spine BMC and T-scores gradually increased during the first 10 years of rhGH replacement and remained stable thereafter. Largest effects of rhGH supplementation were found in men. In the small subset of patients using bisphosphonates, use of bisphosphonates did not impact additional beneficial effects in the long term. Low baseline BMD positively affected the change in BMD and BMC over time, but there was a negative effect of high GH dose at 1 year on the change in BMD and BMC over time. Clinical fracture incidence during long-term rhGH replacement was 20.1/1000 py. CONCLUSIONS: Fifteen years of rhGH replacement in GHD adults resulted in a sustained increase in BMD values at the lumbar spine, particularly in men, and stabilization of BMD values at the femoral neck. Clinical fracture incidence was suggested not to be increased during long-term rhGH replacement.
Subject(s)
Bone and Bones/drug effects , Hormone Replacement Therapy , Human Growth Hormone/deficiency , Human Growth Hormone/therapeutic use , Hypopituitarism/drug therapy , Adult , Bone Density/drug effects , Bone Remodeling/drug effects , Bone and Bones/metabolism , Cohort Studies , Female , Femur Neck , Humans , Hypopituitarism/metabolism , Lumbar Vertebrae , Male , Middle Aged , Recombinant Proteins/therapeutic useABSTRACT
INTRODUCTION: Growth hormone deficiency (GHD) is associated with reduced bone mineral density (BMD). GH replacement has positive effect on BMD but the magnitude of this effect and its mechanism are debated. OBJECTIVES: The objectives of this study was first, to assess the effect of GH replacement on BMD, and second, to evaluate the effect of GH treatment on bone turnover and microarchitecture and to assess the factors influencing the effect of the therapy on BMD. PATIENTS AND METHODS: Adult GHD (AO-GHD) and childhood onset GHD (CO-GHD) patients treated with GH using IGF-I normalization GH replacement regimen were prospectively followed during 2 years. Lumbar spine (L1-L4) and total femur BMD by Hologic discovery, in the subset of patients also bone turnover markers; osteocalcin and carboxy-terminal collagen crosslinks (CTx) were assessed at baseline and at months 3, 6, 12 and 24, respectively. The trabecular bone score (TBS) derived from lumbar spine DXA by the iNsight® software was assessed in a subset of study population at baseline and months 12 and 24. RESULTS: In total, 147 GHD patients (age 35.1 years, 84 males/63 females, 43 of childhood onset GHD/104 AO-GHD) were included. BMD of lumbar spine and femur increased significantly during the treatment (14% and 7% increase at 2 years, respectively; p<0.0001). Bone markers increased during the first 12 months of treatment with subsequent decrease of CTx. At month 24, significant increase in TBS was observed (4%, p=0.02). BMD increase was significantly higher in males (15% increase in males vs. 10% in females, p=0.037) and childhood onset GHD (CO-GHD) patients (13% increase in CO-GHD, p=0.004). CONCLUSION: GH supplementation leads to an increase of BMD with corresponding changes in bone turnover markers and changes in microarchitecture as assessed by trabecular bone score. Positive effect of GH on bone status is more pronounced in males and CO-GHD adults.
Subject(s)
Biomarkers/analysis , Bone Density/drug effects , Bone Development/drug effects , Bone Remodeling/drug effects , Human Growth Hormone/deficiency , Human Growth Hormone/pharmacology , Adult , Age of Onset , Child , Dietary Supplements , Female , Follow-Up Studies , Human Growth Hormone/adverse effects , Humans , Insulin-Like Growth Factor I/analysis , Male , Osteoporosis/drug therapy , Osteoporosis/etiology , Prognosis , Prospective StudiesABSTRACT
The transition period from child to adult represents a crucial phase in the growth process where multiple physical and psychosocial changes occur. It has been arbitrarily defined as the period extending from late puberty to full adult maturity (i.e., from mid to late teenage years until 6-7 years after achievement of final height). The aim of this guideline is to emphasize the importance of adequate hormone replacement during this period and to review reassessment of pituitary function. In patients with GH deficiency diagnosed in childhood, an attempt is made to answer when to retest GH secretion, when to treat and how they should be monitored. Thyroxine, glucocorticoid, and sex steroid replacement are also reviewed.
Subject(s)
Hormone Replacement Therapy , Human Growth Hormone/therapeutic use , Hypopituitarism/drug therapy , Transition to Adult Care , Adolescent , Adult , Body Composition/drug effects , Child , Child Development/drug effects , Drug Monitoring , Endocrine System Diseases/drug therapy , Endocrine System Diseases/etiology , Female , Growth/drug effects , Growth Hormone-Releasing Hormone , Human Growth Hormone/administration & dosage , Human Growth Hormone/deficiency , Humans , Hypothalamo-Hypophyseal System/physiopathology , Male , Pituitary-Adrenal System/physiopathology , PubertyABSTRACT
OBJECTIVES: Previous studies suggested that vitamin D modulates circulating IGF1. We investigated this effect in adults and its clinical relevance in the management of GH deficiency (GHD). DESIGN AND METHODS: IGF1 levels were prospectively measured before and after 12 weeks of treatment with oral vitamin D3 (5000 or 7000âIU/week) vs no intervention in 39 subjects 61.9±7.9 years old. The frequency of IGF1 values ≥50th age- and sex-specific percentile in relation to vitamin D status, as determined by the concentration of 25-hydroxyvitamin D (25(OH)D), was retrospectively assessed in 69 GHD patients (57.4±16.6 years) on stable hormone replacement and with 25(OH)D and IGF1 concurrently measured. RESULTS: Treatment with 5000 and 7000âIU vitamin D3/week significantly raised 25(OH)D by 12.7±8.4 and 13.1±6.5âng/ml respectively (both P<0.001 vs baseline). In the 7000âIU group, IGF1 levels also significantly increased by 31.3±36.7âng/ml (P=0.01). Neither 25(OH)D nor IGF1 significantly varied in controls. IGF1 was ≥50th percentile more frequently in GHD patients with 25(OH)D levels ≥15 than <15âng/ml (65.9 vs 40.0%, P<0.05). Logistic regression with adjustment for recombinant human GH (rhGH) dose, vitamin D supplements, gender, use of thyroid hormones, corticosteroids or estrogen/testosterone, and season revealed a significant positive association between ≥15âng/ml 25(OH)D and IGF1 ≥50th percentile (OR 4.4, 95% CI 1.0-18.8, P<0.05). A significant negative correlation between 25(OH)D concentrations and rhGH dose was found after correcting for age and IGF1 (ß -0.042, P<0.01), but not after further adjusting for sex, thyroid, adrenal or gonadal replacement, and season (ß -0.037, P=0.06). CONCLUSIONS: Vitamin D increases circulating IGF1 in adults. As a result, a better vitamin D status may ease the achievement of normal IGF1 values in GHD.
Subject(s)
Human Growth Hormone/blood , Human Growth Hormone/deficiency , Insulin-Like Growth Factor I/metabolism , Vitamin D Deficiency/drug therapy , Vitamin D/therapeutic use , Vitamins/therapeutic use , Aged , Female , Hormone Replacement Therapy , Humans , Italy , Linear Models , Logistic Models , Male , Medical Records , Middle Aged , Prospective Studies , Retrospective Studies , Treatment Outcome , Vitamin D/administration & dosage , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamins/administration & dosage , Vitamins/bloodABSTRACT
Reduced bone mineral content in growth hormone-deficient children (GHD) has been reported. Calcium, zinc, and vitamin D play an important role in bone formation. Hence, the aim of this pilot randomized controlled study was to evaluate the effect of calcium, vitamin D, and zinc supplementation in prepubertal GHD children treated with GH on bone health parameters. After 1 year of treatment with GH (20 mg/m(2)/week), 31 GHD (mean age 8.7 ± 2.8 years, 18 boys) prepubertal children were randomised to receive calcium (500 mg/day) and vitamin D (60,000 IU/3 months) [Group A] or a similar supplement of calcium, vitamin D, and zinc (as per Indian Recommended Allowance) [Group B] along with GH therapy for the next 12 months. The two groups were similar in anthropometric and body composition parameters at baseline (p > 0.1). After 1 year of GH therapy, height-adjusted % gain was similar in both groups, 48 % in bone mineral content (BMC) and 45 % in bone area (BA). Height-adjusted % increase in BMC was significantly (p < 0.05) higher in the second year than in the first in both the groups. This % increase in BMC and BA was greater in Group B (51 and 36 % respectively) than in Group A (49 and 34 %), although marginally (p < 0.05). Supplementation of calcium and vitamin D along with GH therapy in GHD Indian children has the potential for enhancing bone mass accrual; this effect was further enhanced through the addition of zinc supplement.
Subject(s)
Bone Density/drug effects , Calcium/pharmacology , Dietary Supplements , Human Growth Hormone/therapeutic use , Hypopituitarism/drug therapy , Vitamin D/pharmacology , Zinc/pharmacology , Body Composition/drug effects , Body Height/drug effects , Calcium/therapeutic use , Child , Female , Hormone Replacement Therapy , Human Growth Hormone/deficiency , Humans , Male , Pilot Projects , Treatment Outcome , Vitamin D/therapeutic use , Zinc/therapeutic useABSTRACT
The objective was to study blood Zinc levels and hair Zinc content in three subsets of 40 naive patients (29 boys) with childhood onset GH deficiency (isolated total GHD, partial GHD, syndrome biological inactive GH). Our data showed that GHD in children and adolescents, independently of GHD severity and etiology, is associated with significant decrease of blood zinc level (P < 0.05). This study evaluated the strong link between Zinc and IGF-1 level in GHD children (r = 0.796; P < 0.001). The published data urge to early detection the blood Zinc level in GHD patients and lend support Zn-supplementation in order to optimize the therapeutic regimes for children with GH deficiency.
Subject(s)
Dwarfism, Pituitary/blood , Human Growth Hormone/blood , Human Growth Hormone/deficiency , Zinc/blood , Adolescent , Case-Control Studies , Child , Child, Preschool , Female , Hair/chemistry , Human Growth Hormone/analysis , Humans , Insulin-Like Growth Factor I/metabolism , Male , Zinc/analysisABSTRACT
BACKGROUND/AIMS: To investigate whether short-term changes in body composition as a result of growth hormone therapy could be used to predict its growth effect after 1 year in children with growth hormone deficiency (GHD) and children born small for gestational age (SGA). METHODS: 88 GHD children and 99 SGA children who started treatment with recombinant human growth hormone were included. Total body water (TBW) and height were measured. After 1 year, patients were divided into adequate and inadequate responders. RESULTS: In GHD and SGA children a sensitivity of 87 and 53%, respectively, and a specificity of 58 and 83%, respectively, were found. The positive predictive values for GHD and SGA children were 73 and 90%, respectively. The negative predictive values were 75 and 32%, respectively. CONCLUSION: Changes in body composition data measured by TBW are a valuable tool to correctly predict 75% of the GHD children and are only useful in SGA children when the change in TBW is above the cut-off value of 0.7 l/m(2).
Subject(s)
Biomarkers, Pharmacological , Body Water/drug effects , Growth Disorders/diagnosis , Growth Disorders/drug therapy , Human Growth Hormone/therapeutic use , Infant, Small for Gestational Age/growth & development , Biomarkers, Pharmacological/analysis , Biomarkers, Pharmacological/metabolism , Body Water/metabolism , Body Water/physiology , Child , Child, Preschool , Deuterium , Follow-Up Studies , Growth Disorders/metabolism , Human Growth Hormone/deficiency , Humans , Infant, Newborn , Infant, Small for Gestational Age/metabolism , Predictive Value of Tests , Prognosis , Treatment OutcomeABSTRACT
CONTEXT: Mutations within the PROP1 gene represent one of the main causes of familial combined pituitary hormone deficiency (CPHD). However, most of the cases are sporadic with an unknown genetic cause. OBJECTIVE: The aim of this study was the search for low penetrance variations within and around a conserved regulatory element in the intron 1 of PROP1, contributing to a multifactorial form of the disease in sporadic patients. METHODS AND PATIENTS: A fragment of 570 bp encompassing the conserved region was sequenced in 107 CPHD patients and 294 controls, and an association study was performed with the four identified variants, namely c.109+435G>A (rs73346254), c.109+463C>T (rs4498267), c.109+768C>G (rs4431364), and c.109+915_917ins/delTAG (rs148607624). The functional role of the associated polymorphisms was evaluated by luciferase reporter gene expression analyses and EMSA. RESULTS: A statistically significant increased frequency was observed in the patients for rs73346254A (P = 5 × 10(-4)) and rs148607624delTAG (P = 0.01) alleles. Among all the possible allele combinations, only the haplotype bearing both risk alleles showed a significantly higher frequency in the patients vs. controls (P = 4.7 × 10(-4)) and conferred a carrier risk of 4.19 (P = 1.2 × 10(-4)). This haplotype determined a significant decrease of the luciferase activity in comparison with a basal promoter and the other allelic combinations in GH4C and MCF7 cells (P = 4.6 × 10(-6); P = 5.5 × 10(-4), respectively). The EMSA showed a differential affinity for nuclear proteins for the alternative alleles of the two associated variations. CONCLUSIONS: Variations with a functional significance conferring susceptibility to CPHD have been identified in the PROP1 gene, indicating a multifactorial origin of this disorder in sporadic cases.
Subject(s)
Homeodomain Proteins/genetics , Human Growth Hormone/deficiency , Adolescent , Age of Onset , Cells, Cultured , Child , Child, Preschool , Conserved Sequence , Electrophoretic Mobility Shift Assay , Female , Genetic Variation , Genetic Vectors , Hormones/blood , Humans , Hypothalamus/pathology , Infant , Insulin-Like Growth Factor I/deficiency , Introns/genetics , Luciferases/genetics , Magnetic Resonance Imaging , Male , Mutation/genetics , Mutation/physiology , Penetrance , Pituitary Gland/pathology , Pituitary Hormones/blood , Polymorphism, Single Nucleotide/genetics , Transfection , Young AdultABSTRACT
A 23-year-old male patient, who suffers from beta-thalassemia major, came to us for an endocrine-metabolic evaluation. Medical history showed a diagnosis of heart disease with heart failure since the age of 16, type 1 diabetes mellitus diagnosed at the age of 18, treated with an intensive insulin therapy with a poor glycometabolic control. Patient performed regular blood transfusions and iron chelation with deferasirox. An echocardiogram revealed an enlarged left ventricle. Patient had undergone a comprehensive study of buoyancy both basal and hormone-stimulated and it was therefore carried out a diagnosis of GH deficiency and hypogonadotropic hypogonadism. A recombinant GH replacement therapy was then prescribed. After six months of therapy, the patient reported a net improvement of asthenic symptoms. Physical examination showed a reduction in abdominal adiposity in waist and an increase of 5 cm in stature. Laboratory tests showed an amelioration of glycometabolic control, such as to justify a reduction in daily insulin dose. The stature observed was thought appropriate to begin the administration of testosterone. Moreover, the cardiological framework showed a reduction of left ventricular dilatation, good ventricular motility, global minimum persistent tricuspid but not mitral regurgitation and no alteration on ECG.
Subject(s)
Asthenia/etiology , Diabetes Mellitus, Type 1/etiology , Heart Failure/etiology , Human Growth Hormone/deficiency , Hypogonadism/complications , Iron Overload/etiology , beta-Thalassemia/complications , Blood Transfusion , Cardiovascular Agents/therapeutic use , Chelation Therapy , Combined Modality Therapy , Diabetes Mellitus, Type 1/drug therapy , Diabetes Mellitus, Type 1/metabolism , Dwarfism/drug therapy , Dwarfism/etiology , Growth Hormone/therapeutic use , Heart Failure/drug therapy , Humans , Hypogonadism/diagnosis , Hypogonadism/drug therapy , Insulin/administration & dosage , Insulin/therapeutic use , Iron Chelating Agents/therapeutic use , Male , Mitral Valve Insufficiency/etiology , Testosterone/therapeutic use , Tricuspid Valve Insufficiency/etiology , Young Adult , beta-Thalassemia/drug therapy , beta-Thalassemia/therapyABSTRACT
PURPOSE: To develop a mathematical model utilizing more readily available measures than stimulation tests that identifies brain tumor survivors with high likelihood of abnormal growth hormone secretion after radiotherapy (RT), to avoid late recognition and a consequent delay in growth hormone replacement therapy. METHODS AND MATERIALS: We analyzed 191 prospectively collected post-RT evaluations of peak growth hormone level (arginine tolerance/levodopa stimulation test), serum insulin-like growth factor 1 (IGF-1), IGF-binding protein 3, height, weight, growth velocity, and body mass index in 106 children and adolescents treated for ependymoma (n=72), low-grade glioma (n=28) or craniopharyngioma (n=6), who had normal growth hormone levels before RT. Normal level in this study was defined as the peak growth hormone response to the stimulation test≥7 ng/mL. RESULTS: Independent predictor variables identified by multivariate logistic regression with high statistical significance (p<0.0001) included IGF-1 z score, weight z score, and hypothalamic dose. The developed predictive model demonstrated a strong discriminatory power with an area under the receiver operating characteristic curve of 0.883. At a potential cutoff point of probability of 0.3 the sensitivity was 80% and specificity 78%. CONCLUSIONS: Without unpleasant and expensive frequent stimulation tests, our model provides a quantitative approach to closely follow the growth hormone secretory capacity of brain tumor survivors. It allows identification of high-risk children for subsequent confirmatory tests and in-depth workup for diagnosis of growth hormone deficiency.